Replies to post #238626 on Amarin Corp Plc (AMRN)

[couldbebetter]

Babr, Appreciate your insights from experience. For me it confirms the
need for BP to...uhmm...takeover? sales operations. Some time ago there
was a retired Pfizer sales rep posting his view that if Pfizer owned
Vascepa they would have a 2 year marketing campaign with special
incentives for sales reps to get doctors to write scrips. Once a
doctor is sold on the effectiveness and need for Vascepa they will
continue to write scrips for all of their patients who they believe
would benefit. But it does no good if the doctor is not informed or
might have preconceived notions about a medication without having a
chance to know the facts. In Europe there is no direct to consumer
advertising so the sales rep has an even more critical function.
Vascepa will not sell itself. Vascepa needs an army of sales reps...
ideally those with already established relationships in the CV/Diabetes
specialties.

[Biobillionair]

Babr-

weak marketing to say the least so far.

Agree. But Amarin first needs to get approval through The Office of Prescription Drug Promotion (OPDP).

Here’s more about OPDP:

https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-prescription-drug-promotion-opdp

We know the above process is ongoing because Amarin has stated its ongoing and FDA hasn’t been brave enough to release REDUCE-IT clinical trial snapshot here:

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots

Is Amarin 100% satisfied with label...my opinion is no; FDA should have had a lower TG and prevention of cardiovascular death in indications. Again, this is just my opinion and I don’t care to waste time on nuances of label wording...my only point FDA & Amarin will spend too much time on OPDP process because CDER f’d up labeling....hence marketing delayed until end of Q2.

BB

[postes]

Amrn is doubling the sales force not to see double the DR's but to see 40-50% more DR's and to visit more frequently...hopefully you see an improvement